Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001:1:5.
doi: 10.1186/1471-2210-1-5. Epub 2001 Sep 11.

Omapatrilat normalizes renal function curve in spontaneously hypertensive rats

P Morazo  1 , L A Fortepiani, M Clara Ortíz, N M Atucha, J García-Estañ
Affiliations

Omapatrilat normalizes renal function curve in spontaneously hypertensive rats

P Morazo et al. BMC Pharmacol. 2001.

Abstract

Background: The present study was designed to analyze the chronic renal response to omapatrilat, a new vasopeptidase inhibitor, in spontaneously hypertensive rats (SHR). To that end, the renal and blood pressure response to a 4-day salt loading protocol was analyzed and the respective chronic renal curves constructed.

Results: In non treated animals, and under normal sodium intake (around 2 mEq/day), mean arterial pressure (MAP), was significantly higher in the SHR as compared with the controls (WKY). After increasing salt intake (8 times normal), MAP did not change significantly in any group and the animals reached a normal sodium balance in four days. In a second group of animals, omapatrilat was given orally for 15 days at the dose of 40 mg/kg/day in the drinking water. In these omapatrilat-treated animals, and under normal sodium intake, MAP was significantly lower in both groups, although the antihypertensive effect was much greater in the SHR, so that the MAP of the SHR group was completely normalized and similar to the WKY-treated group. The subsequent elevation of sodium intake did not significantly elevate MAP in any group and the animals could manage the sodium excess as well as the non treated groups.

Conclusions: These results indicate that chronic treatment with omapatrilat normalizes blood pressure in SHR without affecting adversely the renal ability to eliminate a sodium load. Chronic treatment with omapatrilat resets the chronic pressure natriuresis relationship of the SHR to a normal level, thus without altering the normal salt-independence of this arterial hypertension model.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chronic renal function curves in SHR and WKY rats before and during chronic treatment with omapatrilat. MAP, mean arterial pressure.
Figure 2
Figure 2
Daily sodium balance in SHR and WKY rats before and during chronic treatment with omapatrilat. *, p < 0.05 vs groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Burnett JC. Vasopeptidase inhibition. Curr Op Nephrol Hypert. 2000;9:465–468. doi: 10.1097/00041552-200009000-00001. - DOI - PubMed
    1. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363–372. doi: 10.1016/S0895-7061(97)00404-4. - DOI - PubMed
    1. French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol. 1995;26:107–113. - PubMed
    1. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension. 2000;35:1221–1225. - PubMed
    1. Guyton AC. Renal function curve. A key to understanding the pathogenesis of hypertension. Hypertension. 1987;10:1–6. - PubMed

Publication types